[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_96":97},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","mcry3kzxflushsfi5ufh68b9i","revision",2,"title","Lipocine 宣布 Health Canada 批准 TLANDO 用于睾酮替代疗法","originalTitle","Lipocine Inc. (0001535955) (Filer)","summary","Lipocine 于 2026 年 10 月 7 日宣布，Health Canada 批准其产品 TLANDO 用于成年男性的睾酮替代疗法。","reason","source",{"_11":86,"_87":88,"_89":90,"_91":57,"_92":93,"_94":95},"links",{"_83":84,"_63":85},"publishedAt","2026-10-07T10:10:01.000Z","discoveredAt","2026-10-07T10:44:28.256Z","timelineAt","category","ai-products","tags",[81,82],"stockSymbols",[80],"score",32,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","f1j6axmzRkD8",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","52f8b29b-a59b-4638-9c45-b73ccd0daceb","Lipocine 获加拿大批准睾酮替代疗法药物",{"_72":73,"_15":74},"zh","

UNITED\nSTATES

SECURITIES\nAND EXCHANGE COMMISSION

WASHINGTON,\nD.C. 20549

FORM\n8-K

CURRENT\nREPORT

Pursuant\nto Section 13 or 15(d) of

The\nSecurities Exchange Act of 1934

Date\nof Report (Date of Earliest Event Reported):

October\n7, 2026

$\"\"$

LIPOCINE\nINC.

(Exact\nname of registrant as specified in its charter)

Commission\nFile No. 001-36357

\n \n \n \n \n \n \n \n \n

Delaware

99-0370688

(State\n or other jurisdiction

of\n incorporation)

(IRS\n Employer

Identification\n Number)

675\nArapeen Drive, Suite 202

Salt\nLake City, Utah 84108

(Address\nof principal executive offices) (Zip Code)

Registrant’s\ntelephone number, including area code: (801) 994-7383

Former\nname or former address, if changed since last report: Not Applicable

Check\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

☐	Written\n communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting\n material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement\n communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement\n communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities\nregistered pursuant to Section 12(b) of the Act:

\n \n \n \n \n \n \n \n \n \n \n \n \n

Title\n of each class		Trading\n Symbol(s)		Name\n of each exchange on which registered
Common\n Stock, par value $0.0001 per share		LPCN		The\n NASDAQ Stock Market LLC

Indicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §\n230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging\ngrowth company ☐

If\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

\n \n \n \n

Item\n 8.01

Other\n Events

On\nOctober 7, 2026, the Company announced that Health Canada had approved TLANDO^® for testosterone replacement therapy in\nadult males. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein.

\n \n \n \n

Item\n 9.01

Financial\n Statements and Exhibits.

\n \n \n \n

(d)

Exhibits

The\nfollowing exhibits are filed with this report:

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

Exhibit\n No.		Description

99.1		Press Release Lipocine Announces Health Canada Approval of TLANDO^® for Testosterone Replacement Therapy

104		Cover\n Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

		LIPOCINE\n INC.

Date:	October 7, 2026	By:	/s/\n Mahesh V. Patel
			Mahesh\n V. Patel
			President\n and Chief Executive Officer

","zhKind","complete","LPCN","公司与财报","业绩指引","aihot","/items/mcry3kzxflushsfi5ufh68b9i","https://www.sec.gov/Archives/edgar/data/1535955/000149315226046060/0001493152-26-046060-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1791590400&sig=4febbd6b569486c4","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1791590400&sig=b2d04423d06d263c 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1791590400&sig=6668906c0ecbb2a7 96w","changelogVersion","2026-10-01T08:00"]